Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Table 1

Baseline characteristics of the patients.

Characteristics	Group		value
	Ergoferon (n = 140)	Placebo (n = 142)
Age (years)	3.4 (1.8–4.5)	3.2 (2.1–4.6)	1.0
Oral temperature (°С)	38.5 (38.3–38.7)	38.5 (38.3–38.7)	1.0
Flu-like nonspecific symptoms
Decreased activity/weakness (points)	2.0 (1.0–2.0)	2.0 (1.5–2.0)	0.64
Poor appetite/refusal to eat (points)	2.0 (1.0–2.0)	2.0 (1.0–2.0)	1.0
Sick appearance (points)	2.0 (1.0–2.0)	2.0 (1.0–2.0)	1.0
Sleep disturbance (points)	2.0 (1.0–2.0)	1.5 (1.0–2.0)	0.48
Nasal/throat/chest symptoms
Runny nose (points)	1.5 (1.0–2.0)	1.5 (1.0–2.0)	1.0
Stuffy nose/nasal congestion (points)	1.5 (1.0–2.0)	2.0 (1.0–2.0)	0.66
Sneezing (points)	1.0 (0.0–1.0)	1.0 (0.0–1.0)	1.0
Hoarseness (points)	0 (0.0–1.0)	0 (0.0–1.0)	1.0
Sore throat (points)	1.0 (0.0–2.0)	1.0 (0.0–2.0)	1.0
Cough (points)	1.0 (0.0–2.0)	1.0 (0.0–2.0)	1.0
Total symptom severity score (points)	12.3 (9.0–15.0)	13 (11.0–15.5)	0.64

Notes. Values are presented as median and interquartile range (in parentheses). Data were analyzed by Wilcoxon test. values are given with Holm correction for multiple comparisons.